EAHP represents over 29,000 hospital pharmacists across 36 member countries. EAHP represents and develops the hospital pharmacy profession within Europe in order to ensure the continuous improvement of care and outcomes for patients in the hospital setting. This is achieved through science, research, education, practice, as well as sharing best-practice and responsibility with other healthcare professionals.
The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
The EAHP staff supports the Board in executing EAHP’s mission. The Staff assists in financial management, events organisations, policy activities and all EAHP projects. The EAHP staff works closely with EAHP’s members and ensures the effective communication all relevant stakeholders.
The first member countries were Belgium, Britain, Denmark, France, the Federal Republic of Germany and The Netherlands in 1972. EAHP has now 36 EAHP members and 2 Associate Members. EAHP is open to countries members of the Council of Europe and since 2022 to organisations representing the interests of hospital pharmacists from outside the Council of Europe (Associate Membership)
EAHP’s structure is also composed by different standing committes: EAHP Scientific Committee, EAHP Education Executive Committee and the EAHP CTF Steering Committee.
Keep up with all EAHP’s events and webinars. Contact the team at info@eahp.eu should you have any questions about upcoming events or activities.
Here you can find all upcoming events organised by EAHP and by all its members and associate members. Do not hesitate to contact the events team at events@eahp.eu should you have any questions about the organisation of these events.
Hospital pharmacists conduct a critical role in the care of patients in hospitals. Learn more about what they do here and in all the pages under Hospital Pharmacy practice and Policy.
Self-Assessment
SILCC
Closed SIGs
EAHP brings together experts from many areas of hospital pharmacy practice providing and highlighting good local sustainable practices as that can be up-scaled and shared with other countries. The EAHP Working Group on Sustainability has the aim of reducing the environmental burden of the hospital pharmacy services.
The European Association of Hospital Pharmacists (EAHP), and its 36 member country platforms are creating a Common Training Framework for the hospital pharmacy education in Europe. The goal of this project is to allow the free movement of hospital pharmacists within the European Union.
The European Association of Hospital Pharmacists (EAHP) and the European Society of Clinical Pharmacy (ESCP) have collaboratively developed the Oath to Society. The Oath to Society is all encompassing and acts as a contract for excellence in providing compassionate patient care, working as part of the healthcare team and advancing the pharmacy profession, and showcasing how clinical and hospital pharmacists work every day
A day created to highlight the importance and to celebrate the work done by hospital pharmacies. This day celebrates all hospital pharmacy teams.
Catch up with EAHP’s press releases
Find all EAHP relevant publication like the EAHP Surveys, annual reports and the history books.
The European Journal of Hospital Pharmacy (EJHP) is the only official journal of the European Association of Hospital Pharmacists (EAHP) and is committed to advancing the science, practice and profession of hospital pharmacy. As the premier communication platform for hospital pharmacists worldwide, EJHP is a major source for continuing education as well as updates on advances in the practice and standard of pharmaceutical care for patients.
When EAHP and Hospital pharmacists appear in the news.
EAHP publishes a monthly EU monitor with updates about the latest EAHP initiatives and information relevant for the hospital pharmacy profession.
Sponsor Channel
The Sponsor Channel is designed to maximise visibility and engagement, allowing sponsors to connect with the hospital pharmacy community and partners in a dynamic and interactive environment. From product demonstrations to networking sessions, the Sponsor Channel offers a range of opportunities for sponsors to showcase their offerings and generate leads in the new EAHP Website.
WG1
Rahul would like to organise a face-to-face meeting with his WG. When should we do this ideally? During the short phone conversation I had with him he seemed eager to start as soon as possible.
WG4
What are we doing with WG4? Technically this group was set up on a short term basis.
The shortages survey has been promoted via social media, via EAHP presidents/delegates and the Statement ambassadors. In addition, I gave a short presentation on the survey during the last COST action meeting. We will continue with promotion via social media and send a follow-up request for circulation to presidents and delegates in late April/early May.
If possibility Board members should contact their board countries. This is especially important for those countries from which we have received few responses. Aida and Nenad are already working on this for their own countries.
Overall, we have received 323 responses (status on April 11). They come from the following countries: Austria (2), Belgium (35), Bosnia and Herzegovina (9), Croatia (2), Cyprus (1), Denmark (2), Estonia (1), Finland (6), FYROM (1), France (3), Germany (52), Greece (5), Iceland (6), Ireland (13), Italy (11), Latvia (3), Malta (2), Montenegro (2), Netherlands (7), Norway (19), Poland (1), Portugal (57), Romania (4), Russia (1), Serbia (14), Slovakia (9), Slovenia (15), Spain (15), Sweden (3), Switzerland (2), Turkey (10) and the UK (10).
AMR
Steffen will share the final draft on Friday with me.
Procurement
We had a conference call on 30th of March during with the following division of tasks was decided in terms of research contributions:
Rob – the involvement of hospital pharmacists in hospital level procurement and preparation of the first draft
Aida – quality assurance and monitoring
Despoina – why should HPs be involved in procurement on a national level
Stephanie – background information (types of procurement)
The first draft version is available here.
EMA released this week new consultations on GMPs as well as on the Draft European herbal monographs and a call for scientic data for use in HMPC assessment work. I don’t think any of these are relevant to us, unless you see that differently.
The Netherlands is so far the only country that has nominated 3 persons as EMA experts (see here). I plan to share again the request when I send around the minutes from the members meeting to all participants as well as presidents and delegates that were not present at the meeting.
Since a number of president’s guests brought up SDGs, I would like to include it in the policy part of the board meeting under emerging issues.
ESOP
I met with Klaus and Richard to discuss the observatory of the European Biosafety Network. Klaus is opposed to the idea of getting involved due to the close connection to BD. Report HERE
European Biosafety Network
I attended the meeting at European Parliament 10th April on the Madrid model. The meeting was attended by the speakers (see agenda here), RPP, Spanish nurses and Spanish trade union representatives, representatives of BD, representatives of the European Agency for Safety and Health at Work (EU-OSHA), the Bulgarian Drug Agency, a Dutch hospital pharmacist and another hospital pharmacist that represented the interests of ESOP. Apart from me only 2 other EU organisations were present (Richard and Patrick (ECCO) and Melina Raso (Health First Europe)).
Ian used this meeting largely to push is own agenda – i.e. getting the Commission to commit to including hazardous drugs in Annex 1 of the Carcinogen and Mutagen Directive. His speakers (a chemist from Exposure Control Sweden, a representative of the regional government of Madrid, a nurse and a labour law expert that supported the nurse in her legal battle) as well as the MEP (Sion Simon) that chaired the meeting were all in favour of including hazardous drugs in the Carcinogen and Mutagen Directive. In addition, they heavily advocated for the use of closed system transfer devices.
The Commission representative was very cautious with her remarks and also pointed out that not all hazardous drugs cause cancer but also other illness wherefore the Carcinogen and Mutagen Directive might not be the right place to include all of them. The Dutch hospital pharmacists commented on the of closed system transfer devices and stated that the Netherlands is doing very well without them. He asked the Commission to keep their recommendations on devices broad in order to prevent the mandatory use of closed system transfer devices. The lady from ESOP (I think she was Polish and the chair of ESOP’s MASHA Project) raised the same issue. I could not speak to her and the Dutch HP, because they left rather quickly and I was tied up in a conversation with Ian and Richard.
Ian approached Richard and me after the meeting to tell us about his dissatisfaction with the attitude of EAHP and ECCO. He and European Biosafety Network (EBN) are doers that would like to work with us but our processes and politics are stalling the actions he wants to take, wherefore he went ahead without us. ECCO (from what I learned from Richard after the meeting) had expressed the need of transparency and the inclusion of the organisation in decisions taken by EBN in previous conversations with Ian. This was dismissed by Ian, because he cannot be more transparent then he already is and working relations (i.e. who is doing what and contributing how much too the project) grow in his opinion organically once somebody has signed up to the project. Richard disagreed with him on that point and that is where their conversations stopped. Ian has never talked to ESOP, wherefore Richard suggest to him to get in contact with Klaus.
Report HERE
BPP project proposal
Feedback on the proposal (HERE) is requested
Request from RPP
See minutes of March Board meeting.
FIP Call for Nominations for Hospital Pharmacy Section Executive Committee
Inese has expressed interest in joining the Hospital Pharmacy Section Executive Committee of FIP as European Vice-President.
ASHP mid-year international session (December 2018)
ASHP is planning to include a session at the 2018 ASHP Midyear Clinical Meeting & Exposition that will feature short, 20 minute presentations on pharmacy practices from around the world. Abstracts should be submitted by 27th April (COB).
EDQM – Committee of experts on falsified medicines (CMED)
EDQMs Committee of experts on falsified medicines sent me an invitation to present EAHP and activities at their next Committee meeting. External stakeholders – such as EAHP – will get the opportunity to present on 17th May. I send this request to the FMD board leads (you were in CC) but I have not received any feedback, apart from Despoina who told me in person that she cannot attend.
HCPWG meeting EMA
EMA will be speaking about the EMA-HMA collaboration on shortages and availability of medicines to collect stakeholder input for the November 2018 workshop. This is interesting to us.
Healthcare cooperation
Non-Brussels based health professionals associations (podiatrists, dieticians, speech therapists/ logopedists and occupational therapists) are trying to further get in contact with policy officers of Brussels based associations (CPME, CED, PGEU, EAHP). The dieticians are holding their annual meeting in Rotterdam in September. They have suggested to organise a meeting on 27th September to speak about further collaboration. Are we interested?
